---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010182"
form_type: "8-K"
ticker: "HRMY"
cik: "0001802665"
company_name: "Harmony Biosciences Holdings, Inc."
filed_at: "2025-08-05T23:59:59+00:00"
generated_at: "2026-05-17T20:54:24.867067+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Harmony Biosciences Q2 revenue $200.5M (+16% YoY); EPS $0.68; reaffirms FY guidance $820-860M

## Summary
- Net product revenue $200.5M (+16% YoY); GAAP net income $39.8M ($0.68 diluted EPS); non-GAAP adj. net income $53.8M ($0.92 diluted EPS).
- Reaffirms 2025 revenue guidance $820M-$860M; added 400 average patients to 7,600 in Q2.
- Phase 3 ZYN002 topline data in Fragile X syndrome on track for Q3 2025; targets ~80K U.S. patients.
- Entered research collaboration with CiRC Biosciences for refractory epilepsy & narcolepsy; $15M upfront paid.
- Settled ANDA litigation with Lupin; generic launch no earlier than Jan 2030 (or July 2030 with pediatric exclusivity).

## SEC filing metadata
- accession: 0001558370-25-010182
- form_type: 8-K
- ticker: HRMY
- cik: 0001802665
- company_name: Harmony Biosciences Holdings, Inc.
- filed_at: 2025-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/0001558370-25-010182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802665/000155837025010182/hrmy-20250805x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010182
- JSON: https://secwatch.observer/filing/0001558370-25-010182.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.